-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 16, 2020, according to the latest publicity from the Drug Review Center (CDE) of the State Drug Administration of China, ZM-H1505R, a new class of drug declared by Shanghai-based ZM-H1505R, obtained a clinical trial to conduct safety and anti-hepatitis B virus effectiveness trials in patients with chronic hepatitis B.
according to company-released information, the company obtained the FDA's ZM-H1505R clinical trial license on January 14 this year, and in February in the United States in healthy people launched a clinical Ia trial.
that the Ia clinical trial has been completed, and some of the results of the clinical study were presented at this month's U.S. Liver Conference.
photo source: CDE official website screenshots are different from other types I (sacin) and II (sulfonamide) HBV core protein variant regulator (CpAMs), ZM-H1505R is A completely new structure of pyridoxine-like nuclear crust inhibitors, by interfering with the normal formation of viral nuclear casings and hindering the packaging of pre-genome RNA (PgRNA), and effectively block the replication of hepatitis B virus, and effectively block the formation of HBV cccDNA.
ZM-H1505R is the first clinical product to enter the HBV development pipeline for The League Pharmaceuticals.
In the field of chronic hepatitis B treatment, Pharma's product pipeline covers multiple aspects of the life cycle of the hepatitis B virus, including antiviral replication of nuclear casing inhibitors, RNA destabilizers that inhibit the expression of surface antigens and other proteins of the hepatitis B virus, and immunomodulation agents.
it is learned that the development strategy of the company is to suppress the replication of the virus in many directions, the expression of viral proteins, while inducing an effective antiviral immune response to suppress the virus, and ultimately achieve a functional cure of chronic hepatitis B.
note: There are deletions in the original text